PL3549949T3 - Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania - Google Patents

Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania

Info

Publication number
PL3549949T3
PL3549949T3 PL19167276.5T PL19167276T PL3549949T3 PL 3549949 T3 PL3549949 T3 PL 3549949T3 PL 19167276 T PL19167276 T PL 19167276T PL 3549949 T3 PL3549949 T3 PL 3549949T3
Authority
PL
Poland
Prior art keywords
methods
clostridium difficile
difficile toxin
compositions relating
mutant clostridium
Prior art date
Application number
PL19167276.5T
Other languages
English (en)
Inventor
Maninder K. Sidhu
Annaliesa Sybil Anderson
Robert G. K. Donald
Kathrin Ute Jansen
Narender K. Kalyan
Terri L. MININNI
Justin Keith Moran
Mark E. Ruppen
Michael James Flint
Original Assignee
Wyeth Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Llc filed Critical Wyeth Llc
Publication of PL3549949T3 publication Critical patent/PL3549949T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/99—Enzyme inactivation by chemical treatment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL19167276.5T 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania PL3549949T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161478474P 2011-04-22 2011-04-22
US201161478899P 2011-04-25 2011-04-25

Publications (1)

Publication Number Publication Date
PL3549949T3 true PL3549949T3 (pl) 2024-04-08

Family

ID=46085103

Family Applications (3)

Application Number Title Priority Date Filing Date
PL19167276.5T PL3549949T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostriudium difficile i sposoby ich wytwarzania
PL12720966T PL2699587T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną C. difficile i sposoby ich wytwarzania
PL19151036.1T PL3505531T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania

Family Applications After (2)

Application Number Title Priority Date Filing Date
PL12720966T PL2699587T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną C. difficile i sposoby ich wytwarzania
PL19151036.1T PL3505531T3 (pl) 2011-04-22 2012-04-20 Kompozycje związane ze zmutowaną toksyną Clostridium difficile i sposoby ich wytwarzania

Country Status (30)

Country Link
US (13) US8481692B2 (pl)
EP (4) EP4365196A3 (pl)
JP (8) JP5917682B2 (pl)
KR (1) KR101667837B1 (pl)
CN (3) CN111647059B (pl)
AR (1) AR086199A1 (pl)
AU (6) AU2012245904B2 (pl)
BR (2) BR122019017005B1 (pl)
CA (1) CA2832712C (pl)
CO (1) CO6801643A2 (pl)
DK (2) DK3549949T5 (pl)
ES (3) ES2969952T3 (pl)
FI (1) FI3549949T3 (pl)
HR (2) HRP20240042T1 (pl)
HU (2) HUE047085T2 (pl)
IL (8) IL270779B2 (pl)
MX (3) MX391236B (pl)
MY (2) MY182429A (pl)
NZ (1) NZ616035A (pl)
PE (2) PE20181334A1 (pl)
PH (1) PH12013502178B1 (pl)
PL (3) PL3549949T3 (pl)
PT (2) PT2699587T (pl)
RU (2) RU2592686C2 (pl)
SA (3) SA115360698B1 (pl)
SG (3) SG10201911993UA (pl)
SI (3) SI2699587T1 (pl)
TW (6) TWI701257B (pl)
WO (1) WO2012143902A1 (pl)
ZA (1) ZA201307818B (pl)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2054044B1 (de) * 2006-08-02 2014-07-23 Johannes Gutenberg-Universität Mainz Arzneimittel gegen lct-vergiftungen
EP2376107B1 (en) * 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201016742D0 (en) * 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
AU2012245904B2 (en) * 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
CN104662044B (zh) 2012-08-24 2018-10-30 加利福尼亚大学董事会 用于治疗ror1癌症并抑制转移的抗体和疫苗
US20140081659A1 (en) 2012-09-17 2014-03-20 Depuy Orthopaedics, Inc. Systems and methods for surgical and interventional planning, support, post-operative follow-up, and functional recovery tracking
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
JP6321667B2 (ja) * 2012-11-06 2018-05-09 バイエル・ファルマ・アクティエンゲゼルシャフト 二重特異性Ｔ細胞エンゲージャー（ＢｉＴＥｓ）のための配合物
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
JP2016518374A (ja) * 2013-04-22 2016-06-23 ボード オブ リージェンツ オブ ザ ユニバーシテイ オブ オクラホマ クロストリジウム・ディフィシルワクチン及び使用方法
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
US9717711B2 (en) 2014-06-16 2017-08-01 The Lauridsen Group Methods and compositions for treating Clostridium difficile associated disease
DK3174553T3 (en) * 2014-07-25 2018-07-23 Biosynth Srl GLYCOCOONJUGATE VACCINES INCLUDING BASIC UNITS OF A MOLECULE CONSTRUCTION THAT EXPRESSES MULTIPLE INTEGRATED EPITOPES FOR THE FORMULATION OF A WIDE-SPECTED VACCINE AGAINST INFECTIONS BASED ON BACTEROGEN
EP3256855B1 (en) * 2015-02-13 2020-10-07 Quanterix Corporation Immunoassays for diffrential detection of clostridium difficile
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
KR20240113990A (ko) 2016-06-27 2024-07-23 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 암 치료 조합
US20190211377A1 (en) * 2016-12-22 2019-07-11 Roche Molecular Systems, Inc. Cobra probes to detect a marker for epidemic ribotypes of clostridium difficile
IL320444A (en) * 2017-09-28 2025-06-01 Pfizer Compositions and methods for stimulating an immune response against Clostridium difficile
WO2020201985A1 (en) * 2019-04-01 2020-10-08 Pfizer Inc. Compositions and methods for eliciting an immune response against clostridium difficile
WO2020231859A1 (en) * 2019-05-10 2020-11-19 The Board Of Regents Of The University Of Oklahoma Clostridioides difficile tcdb variants, vaccines and methods of use
WO2020231930A1 (en) * 2019-05-11 2020-11-19 The Texas A&M University System Protein inhibitors of clostridium difficile toxin b
KR102376876B1 (ko) 2020-04-09 2022-03-21 대진대학교 산학협력단 무독성의 클로스트리디움 디피실 독소단백질-단편 및 이의 용도
EP4146200A4 (en) * 2020-05-06 2024-05-15 Albert Einstein College of Medicine AGENTS FOR PREVENTING TISSUE DAMAGE RELATED TO CLOSTRIDIUM DIFFICILE INFECTIONS BY INHIBITING THE BACTERIAL TOXINS TCDA AND TCDB DAMAGED THE INTESTIN
WO2021255690A2 (en) 2020-06-19 2021-12-23 Pfizer Inc. Immunogenic compositions against clostridioides (clostridium) difficile and methods thereof
CN111755068B (zh) * 2020-06-19 2021-02-19 深圳吉因加医学检验实验室 基于测序数据识别肿瘤纯度和绝对拷贝数的方法及装置
CA3254452A1 (en) 2022-03-14 2023-09-21 Pfizer Inc. ADJUVANT PRODUCTION PROCESSES
US20250213667A1 (en) 2022-06-01 2025-07-03 Valneva Austria Gmbh Clostridium difficile vaccine
CN120475988A (zh) 2022-12-13 2025-08-12 辉瑞公司 免疫原性组合物及引发针对艰难梭菌的免疫应答的方法
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition
WO2024196707A2 (en) * 2023-03-17 2024-09-26 The Board Of Trustees Of The University Of Illinois Chimeric antibody molecules based on tetrameric teleost immunoglobulin m
WO2025057058A1 (en) 2023-09-13 2025-03-20 Pfizer Inc. Methods for producing an adjuvant
WO2025257712A1 (en) * 2024-06-12 2025-12-18 Pfizer Inc. Immunogenic compositions and methods for eliciting an immune response against clostridioides (clostridium) difficile

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58216123A (ja) 1982-06-10 1983-12-15 Kazue Ueno 抗血清
US4689299A (en) 1982-09-30 1987-08-25 University Of Rochester Human monoclonal antibodies against bacterial toxins
US4713240A (en) 1985-04-04 1987-12-15 Research Corporation Vaccines based on insoluble supports
US5358868A (en) 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5599539A (en) 1989-10-31 1997-02-04 Ophidian Pharmaceuticals, Inc. Therapy for clostridial botulinum toxin
US5919665A (en) 1989-10-31 1999-07-06 Ophidian Pharmaceuticals, Inc. Vaccine for clostridium botulinum neurotoxin
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
US5578308A (en) 1990-02-12 1996-11-26 Capiau; Carine Glutaraldehyde and formalin detoxified bordetella toxin vaccine
US5231003A (en) 1990-05-11 1993-07-27 Cambridge Bioscience Corporation Monoclonal antibodies specific for toxin b of clostridium difficile
JPH06509866A (ja) 1991-04-22 1994-11-02 マサチューセッツ　ヘルス　リサーチ　インスティチュート，インコーポレーテッド 呼吸系ウイルスに対する有効な抗体力価用の血漿試料をスクリーニングする方法
US6221363B1 (en) 1991-07-11 2001-04-24 Baxter Aktiengesellschaft Vaccine for the prevention of lyme disease
JP4129544B2 (ja) 1993-03-29 2008-08-06 ファイザー・インク サポニンアジュバント使用の多成分系クロストリジウム・ワクチン
NZ291659A (en) 1994-09-06 2001-04-27 Galagen Inc Use in the manufacture of a medicament of an antibody having specific activity against Clostridium difficile, and pharmaceutical compositions comprising Anti-Clostridium difficile bovine immunoglobulin concentrate; for treating diseases associated with Clostridium difficile
BR9509903A (pt) * 1994-10-24 1997-11-25 Ophidian Pharm Inc Proteína de fusão proteína de fus o solúvel composição de matéria célula hospedeira processo para gerar uma antiotoxina neutralizante dirigida contra toxina tipo a de clostridium botulinum anticorpo processo para purificar uma proteina de fusão recombinante derivada de uma toxina tipo a de clostridium botulinum processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo b de clostridium difficile anticorpo processo de tratemento processo para gerar uma antitoxina neutralizante dirigida contra toxina tipo a de clostridium difficile composição processo para vacinar um individuo para produzir antitoxina neutralizante dirigida contra toxina de clostridium difficile processo a detecção de antigenos de clostridium difficile em uma amosta processo de purificação de toxinas de clostridium difficile de uma cultura e processo de generação de uma forma dosagem sólida de uma antitoxina de ave dirigida contra uma proteina de toxina clostridial
US6743430B1 (en) 1995-03-29 2004-06-01 Richard E. Parizek Multicomponent vaccine containing clostridial and non-clostridial organisms in a low dose
US5610023A (en) 1995-03-31 1997-03-11 Lee Laboratories, Inc. Method of purification of clostridium difficile toxin A and production of mono-specific antibodies
JPH11510793A (ja) 1995-07-07 1999-09-21 オラバックス インク． 胃腸病に対する鼻腔内ワクチン接種
US5919463A (en) 1995-07-07 1999-07-06 Oravax, Inc. Clostridium difficle toxins as mucosal adjuvants
DE69610106D1 (de) 1995-07-07 2000-10-05 Oravax Inc Toxine und toxoide von clostridium difficile als schleimhautadjuvans
CA2232001C (en) * 1995-09-15 2002-12-10 Dale N. Gerding Methods and compositions for prevention and treatment of clostridium difficile-associated diseases
BR9712092A (pt) 1996-07-12 1999-08-31 Edwin C Iliff Sistema computadorizado para diagnóstico clínico e aconselhamento de tratamento incluindo acesso a rede.
ATE272409T1 (de) 1996-09-30 2004-08-15 Univ Arkansas Verfahren zur erzeugung aktiver immunität durch vakzinkonjugate
US20100267012A1 (en) 1997-11-04 2010-10-21 Bergeron Michel G Highly conserved genes and their use to generate probes and primers for detection of microorganisms
EP2172216A3 (en) 1997-03-10 2010-11-24 Ottawa Hospital Research Institute Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
US20050106157A1 (en) 1997-05-27 2005-05-19 Deckers Harm M. Immunogenic formulations comprising oil bodies
EP1000155A1 (en) 1997-06-20 2000-05-17 QUEEN MARY & WESTFIELD COLLEGE Immunogenic fragments of toxin a of clostridium difficile
DE19739685A1 (de) * 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6214341B1 (en) 1997-10-20 2001-04-10 Oravax Passive immunization against Clostridium difficile disease
EP1568378B1 (en) 1997-10-20 2016-03-16 Sanofi Pasteur Biologics, LLC Immunization against Clostridium difficile disease
US6733760B1 (en) 1999-04-09 2004-05-11 Techlab, Inc. Recombinant toxin A/toxin B vaccine against Clostridium difficile
JP2002541808A (ja) * 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
EP1169456B1 (en) 1999-04-09 2012-07-11 Intercell USA, Inc. Recombinant production of Clostridium difficile Toxin A or Toxin B
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
GB0008682D0 (en) 2000-04-07 2000-05-31 Microbiological Res Authority Transformation of clostridium difficile
PL365453A1 (pl) * 2000-05-04 2005-01-10 President And Fellows Of Harvard College Związki i sposoby do leczenia i zapobiegania zakażeniom bakteryjnym
DE60217107T2 (de) * 2001-06-20 2007-08-23 Ramot At Tel Aviv University Ltd. Mehrantigenisches peptid enthaltend mehrere kopien eines epitopes von einem ablagerungsformenden polypeptid und dessen verwendung
US20040029129A1 (en) * 2001-10-25 2004-02-12 Liangsu Wang Identification of essential genes in microorganisms
WO2003104453A1 (ja) 2002-06-05 2003-12-18 中外製薬株式会社 抗体作製方法
WO2004041857A2 (en) * 2002-06-17 2004-05-21 Ballard Jimmy D Mutant of clostridium difficile toxin b and methods of use
US20040235139A1 (en) 2002-12-23 2004-11-25 Demain Arnold L. Clostridium difficile culture and toxin production methods
JP4597123B2 (ja) * 2003-03-13 2010-12-15 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 細菌性細胞溶解素の精製方法
US20050020506A1 (en) 2003-07-25 2005-01-27 Drapeau Susan J. Crosslinked compositions comprising collagen and demineralized bone matrix, methods of making and methods of use
PL1709170T3 (pl) 2004-01-16 2018-06-29 Pfenex Inc. Ekspresja białek ssaczych w Pseudomonas fluorescens
NZ530709A (en) 2004-01-21 2006-07-28 Agres Ltd Improved IGA production method
JP4588763B2 (ja) * 2004-02-06 2010-12-01 ユニバーシティー オブ マサチューセッツ クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体およびその使用
GB0421083D0 (en) * 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
WO2006130925A1 (en) 2005-06-10 2006-12-14 Monash University Genetic manipulation of clostridium difficile
GB0512751D0 (en) 2005-06-22 2005-07-27 Glaxo Group Ltd New adjuvant
WO2007090126A2 (en) * 2006-01-30 2007-08-09 Invitrogen Corporation Compositions and methods for detecting and quantifying toxic substances in disease states
US20070243212A1 (en) * 2006-03-30 2007-10-18 Embrex, Inc. Methods and compositions for vaccination of poultry
WO2007146139A2 (en) * 2006-06-08 2007-12-21 Cornell Research Foundation, Inc. Codon-optimized dna molecules encoding the receptor binding domains of clostridium difficile toxins a and b
GB0612301D0 (en) 2006-06-21 2006-08-02 Morvus Technology Ltd DNA molecules and methods
US20080206819A1 (en) 2006-08-21 2008-08-28 Mary Tsao Intensified Perfusion Production Method
US7775167B2 (en) 2006-08-22 2010-08-17 Monsanto Technology Llc Custom planter and method of custom planting
EP2813144A1 (en) 2006-10-09 2014-12-17 Charleston Laboratories, Inc. Analgesic compositions comprising an antihistamine
US9023352B2 (en) * 2007-02-20 2015-05-05 Tufts University Methods, compositions and kits for treating a subject using a recombinant heteromultimeric neutralizing binding protein
JP5164970B2 (ja) * 2007-03-02 2013-03-21 パナソニック株式会社 音声復号装置および音声復号方法
EP2014760A1 (en) 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process
US9096638B2 (en) 2007-09-06 2015-08-04 Geneohm Sciences Canada, Inc. Detection of toxigenic strains of Clostridium difficile
CN101855336B (zh) * 2007-09-14 2019-07-30 赛诺菲巴斯德生物制剂有限责任公司 含艰难梭菌类毒素a和b的药物组合物
WO2009132082A2 (en) * 2008-04-22 2009-10-29 Medical College Of Georgia Research Institute, Inc. Immunogenic compositions containing ceramide and methods of use thereof
US8206940B2 (en) 2008-05-15 2012-06-26 Tufts University Methods for diagnosis of Clostridium difficile and methods and vectors for recombinant toxin expression
WO2009156852A1 (en) 2008-06-25 2009-12-30 Novartis Ag Rapid responses to delayed booster immunisations
EP2146490A1 (en) 2008-07-18 2010-01-20 Alcatel, Lucent User device for gesture based exchange of information, methods for gesture based exchange of information between a plurality of user devices, and related devices and systems
US20120020996A1 (en) 2008-08-06 2012-01-26 Jonathan Lewis Telfer Vaccines against clostridium difficile and methods of use
US9115347B2 (en) 2008-09-24 2015-08-25 Sanofi Pasteur Biologies, LLC Methods and compositions for increasing toxin production
US8444996B2 (en) 2008-10-01 2013-05-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
SG171934A1 (en) 2008-12-03 2011-07-28 Boehringer Ingelheim Vetmed Process for production of vaccines
EP2376107B1 (en) 2008-12-09 2014-05-21 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB0901001D0 (en) * 2009-01-22 2009-03-04 Univ Nottingham Methods
EP2405940B1 (en) * 2009-02-20 2021-08-04 Secretary of State for Health and Social Care Antibodies to clostridium difficile toxins
EP2470664A4 (en) * 2009-08-27 2013-01-16 Synaptic Res Llc NEW PROTEIN RELEASE SYSTEM FOR GENERATING INDUCED PLURIPOTENTAL STEM CELLS OR TISSUE-SPECIFIC CELLS
WO2011060431A2 (en) * 2009-11-16 2011-05-19 University Of Maryland Baltimore Multivalent live vector vaccine against clostridium difficile-associated disease
AU2010325992A1 (en) * 2009-12-02 2012-05-31 Tufts University Atoxic recombinant holotoxins of Clostridium difficile as immunogens
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
TW201136603A (en) * 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CN101870978A (zh) * 2010-03-23 2010-10-27 王世霞 密码子优化的艰难梭菌外毒素a羧基端基因序列及其核酸疫苗
US8530171B2 (en) 2010-03-30 2013-09-10 Pfenex Inc. High level expression of recombinant toxin proteins
US8765399B2 (en) 2010-05-18 2014-07-01 Montefiore Medical Center Cultures and protocols for diagnosis of toxigenic Clostridium difficile
JP6121421B2 (ja) 2010-09-03 2017-04-26 バルネバ オーストリア ジーエムビーエイチ Ｃ．ディフィシルの毒素ａおよび毒素ｂタンパク質の単離ポリペプチドならびにその使用
GB201016742D0 (en) 2010-10-05 2010-11-17 Health Prot Agency Clostridium difficile antigens
WO2012078313A2 (en) * 2010-11-12 2012-06-14 Reflexion Pharmaceuticals, Inc. Gb1 peptidic libraries and compounds, and methods of screening the same
AU2012245904B2 (en) 2011-04-22 2016-04-21 Wyeth Llc Compositions relating to a mutant Clostridium difficile toxin and methods thereof
US9290565B2 (en) 2011-05-27 2016-03-22 Glaxosmithkline Biologicals, S.A. Immunogenic composition
WO2012166991A1 (en) * 2011-05-31 2012-12-06 The Board Of Regents Of The University Of Texas Systeem S-nitrosylation of glucosylating toxins and uses therefor
CN103974718A (zh) 2011-12-08 2014-08-06 诺华股份有限公司 基于艰难梭菌毒素的疫苗
AR089797A1 (es) 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
MX2015002485A (es) 2012-09-19 2015-06-05 Novartis Ag Polipeptidos de clostridium difficile como vacuna.
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US10117933B2 (en) 2012-11-28 2018-11-06 Emergent Biosolutions Canada Inc. Antibodies against Clostridium difficile
LT2928489T (lt) 2012-12-05 2019-04-10 Glaxosmithkline Biologicals S.A. Imunogeninė kompozicija
GB201223342D0 (en) 2012-12-23 2013-02-06 Glaxosmithkline Biolog Sa Immunogenic composition
WO2014144292A2 (en) 2013-03-15 2014-09-18 Sanofi Pasteur Biologics , Llc Antibodies against clostridium difficile toxins and methods of using the same
JP2016516721A (ja) 2013-03-15 2016-06-09 サノフィ パストゥール インコーポレイテッド トキソイド、組成物および関連方法
US20170165375A1 (en) 2013-04-02 2017-06-15 Stc. Unm Antibiotic protocells and related pharmaceutical formulations and methods of treatment
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
EP3060246A4 (en) 2013-10-23 2017-08-16 The Rockefeller University Compositions and methods for prophylaxis and therapy of clostridium difficile infection
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US10947494B2 (en) 2015-11-17 2021-03-16 Pfizer Inc. Media and fermentation methods for producing polysaccharides in bacterial cell culture
US10813988B2 (en) 2016-02-16 2020-10-27 President And Fellows Of Harvard College Pathogen vaccines and methods of producing and using the same
IL269258B2 (en) 2017-03-15 2023-09-01 Novavax Inc Methods and compositions for inducing immune responses against Clostridium difficile
CA3016351A1 (en) 2017-09-05 2019-03-05 Mcmaster University Aptamers for clostridium difficile detection
IL320444A (en) 2017-09-28 2025-06-01 Pfizer Compositions and methods for stimulating an immune response against Clostridium difficile
JP6704173B2 (ja) 2019-09-26 2020-06-03 パナソニックＩｐマネジメント株式会社 開閉器及び分電盤

Also Published As

Publication number Publication date
EP3505531A1 (en) 2019-07-03
CN107022532B (zh) 2021-05-04
PL2699587T3 (pl) 2019-12-31
IL254440A0 (en) 2017-11-30
IL270779B1 (en) 2024-05-01
ES2742823T3 (es) 2020-02-17
JP2019052149A (ja) 2019-04-04
IL270779A (en) 2020-01-30
JP6892425B2 (ja) 2021-06-23
US8481692B2 (en) 2013-07-09
PL3505531T3 (pl) 2024-03-11
TWI815599B (zh) 2023-09-11
SG10201602668VA (en) 2016-05-30
DK3549949T3 (da) 2023-12-18
CN111647059B (zh) 2023-11-28
US20130330371A1 (en) 2013-12-12
IL254440B (en) 2019-12-31
US9187536B1 (en) 2015-11-17
HUE047085T2 (hu) 2020-04-28
ES2969952T3 (es) 2024-05-23
CN103619871B (zh) 2016-12-14
US20150307563A1 (en) 2015-10-29
AU2016202903A1 (en) 2016-05-26
RU2592686C2 (ru) 2016-07-27
EP3549949A1 (en) 2019-10-09
PE20141029A1 (es) 2014-09-04
JP6735784B2 (ja) 2020-08-05
USRE46518E1 (en) 2017-08-22
IL254418A0 (en) 2017-11-30
EP3505531B1 (en) 2023-11-15
IL245047A0 (en) 2016-05-31
ZA201307818B (en) 2014-06-25
IL228944A (en) 2017-11-30
TWI804717B (zh) 2023-06-11
ES2968629T3 (es) 2024-05-13
FI3549949T3 (fi) 2024-01-30
AU2016202903B2 (en) 2017-11-30
TW201302780A (zh) 2013-01-16
IL270779B2 (en) 2024-09-01
CO6801643A2 (es) 2013-11-29
US10597428B2 (en) 2020-03-24
SI3549949T1 (sl) 2024-02-29
TWI686402B (zh) 2020-03-01
EP2699587B1 (en) 2019-07-03
JP2017125030A (ja) 2017-07-20
IL254418B (en) 2019-12-31
BR112013027229B1 (pt) 2020-10-27
TWI701257B (zh) 2020-08-11
WO2012143902A1 (en) 2012-10-26
CN111647059A (zh) 2020-09-11
JP2018052938A (ja) 2018-04-05
AU2020230248B2 (en) 2022-12-01
USRE48862E1 (en) 2021-12-28
EP4365196A2 (en) 2024-05-08
TWI650329B (zh) 2019-02-11
US20200095290A1 (en) 2020-03-26
SI3505531T1 (sl) 2024-02-29
MX385834B (es) 2025-03-18
AR086199A1 (es) 2013-11-27
AU2017261465A1 (en) 2017-11-30
SA115360697B1 (ar) 2016-04-05
JP2021130692A (ja) 2021-09-09
RU2013145170A (ru) 2015-06-27
JP2016117745A (ja) 2016-06-30
SG10201911993UA (en) 2020-02-27
US20150125927A1 (en) 2015-05-07
RU2015154443A3 (pl) 2019-05-22
JP2022126822A (ja) 2022-08-30
JP6321239B2 (ja) 2018-05-09
US8557548B2 (en) 2013-10-15
AU2019246878A1 (en) 2019-10-31
US20190202873A1 (en) 2019-07-04
US9745354B2 (en) 2017-08-29
IL273231B (en) 2021-08-31
JP2018135345A (ja) 2018-08-30
TW201932480A (zh) 2019-08-16
SA115360698B1 (ar) 2016-04-27
SI2699587T1 (sl) 2019-08-30
CA2832712A1 (en) 2012-10-26
MX2013012344A (es) 2013-11-20
JP5917682B2 (ja) 2016-05-18
RU2754446C2 (ru) 2021-09-02
JP6097853B2 (ja) 2017-03-15
EP3549949B1 (en) 2023-11-29
EP2699587A1 (en) 2014-02-26
IL265510B (en) 2021-05-31
IL255345A0 (en) 2017-12-31
IL265510A (en) 2019-05-30
US8900597B2 (en) 2014-12-02
USRE46376E1 (en) 2017-04-25
AU2019246878B2 (en) 2020-09-10
PT2699587T (pt) 2019-09-05
USRE48863E1 (en) 2021-12-28
DK3549949T5 (da) 2024-09-02
IL273231A (en) 2020-04-30
AU2012245904A1 (en) 2013-10-17
MY182429A (en) 2021-01-25
TW201932481A (zh) 2019-08-16
US10774117B2 (en) 2020-09-15
IL255345B (en) 2021-05-31
MX347521B (es) 2017-04-27
AU2012245904B2 (en) 2016-04-21
CN103619871A (zh) 2014-03-05
PH12013502178A1 (en) 2014-01-13
TW202041525A (zh) 2020-11-16
HRP20231631T1 (hr) 2024-03-15
EP4365196A3 (en) 2024-08-07
CA2832712C (en) 2018-08-28
AU2017261465B2 (en) 2018-10-04
BR122019017005B1 (pt) 2022-03-29
HUE065594T2 (hu) 2024-06-28
TWI671313B (zh) 2019-09-11
PE20181334A1 (es) 2018-08-21
KR20130140206A (ko) 2013-12-23
US20170313749A1 (en) 2017-11-02
US20230391835A1 (en) 2023-12-07
CN107022532A (zh) 2017-08-08
IL228944A0 (en) 2013-12-31
RU2015154443A (ru) 2019-01-17
NZ616035A (en) 2016-03-31
MX391236B (es) 2025-03-21
PH12013502178B1 (en) 2018-11-09
JP2014514318A (ja) 2014-06-19
MY168205A (en) 2018-10-15
AU2018201296A1 (en) 2018-03-15
KR101667837B1 (ko) 2016-10-20
PT3549949T (pt) 2024-02-02
US20120269841A1 (en) 2012-10-25
JP7097478B2 (ja) 2022-07-07
TW201806967A (zh) 2018-03-01
AU2020230248A1 (en) 2020-10-01
US11535652B2 (en) 2022-12-27
TW202320843A (zh) 2023-06-01
SA112330472B1 (ar) 2015-11-02
US20130244307A1 (en) 2013-09-19
SG194132A1 (en) 2013-11-29
BR112013027229A2 (pt) 2016-11-29
DK2699587T3 (da) 2019-08-05
HRP20240042T1 (hr) 2024-03-29

Similar Documents

Publication Publication Date Title
IL273231B (en) Clostridium difficile toxin-related preparations and methods
IL284582A (en) Compositions and methods related to mutant Clostridium difficile toxin
SG10201602218VA (en) Novel fuel compositions and methods for making same
IL228607A0 (en) A preparation of lyophilized botulinum toxins
EP2668281A4 (en) COMPOSITIONS AND METHODS OF SUCCINATE MANUFACTURE
PL2731963T3 (pl) Kompozycje i sposoby do immunomodulacji
ZA201308892B (en) Compositions and methods
PL2841593T3 (pl) Dehydrogenaza i toksyna clostridium difficile jako biomarker
HUE050699T2 (hu) Készítmények és eljárások Spirocheták tenyésztésére
PL2729139T3 (pl) Produkt zmniejszający kaszel
GB201116340D0 (en) Compositions and methods